This trial is testing the safety of combining two drugs to treat gastroesophageal cancer and other gastrointestinal cancers. The goal is to find a more effective therapy for these patients.
- Stomach Cancer
- Esophageal Cancer
- Liver Cancer
- Colorectal Cancer
2 Primary · 4 Secondary · Reporting Duration: Every 8 weeks for 12 months
4 Treatment Groups
Cabozantinib plus Durvalumab (Gastric & esophageal cancer cohort)
1 of 4
Cabozantinib plus Durvalumab (Hepatocellular carcinoma cohort)
1 of 4
Cabozantinib plus Durvalumab (Colorectal cancer cohort)
1 of 4
Cabozantinib plus Durvalumab plus Tremelimumab (Hepatocellular carcinoma cohort)
1 of 4
117 Total Participants · 4 Treatment Groups
Primary Treatment: Durvalumab · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 15 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What are the most common conditions that doctors use Durvalumab to manage?
"The therapeutic benefits of Durvalumab have been observed in patients with a pre-existing condition, those who have received anti-vegf treatments, and those who supplement their amino acids." - Anonymous Online Contributor
Does this program still have room for more participants?
"That is accurate. The clinical trial in question, which can be found on clinicaltrials.gov, is seeking patients at the moment. This specific study was posted on October 22nd, 2018 and updated as recently as May 8th, 2022. There is a total goal of 117 patients across 1 location." - Anonymous Online Contributor
What other research exists on this topic?
"AstraZeneca first began sponsoring research into Durvalumab in 2007. That year, the drug underwent its first clinical trial. After Phase 2 approval was granted in 2007, following a 37 person study, today there are 501 active trials involving Durvalumab being conducted across 2003 cities and 60 countries." - Anonymous Online Contributor
What is the extensive history of Durvalumab in previous medical research?
"501 clinical trials are being conducted for Durvalumab globally. Out of these, 67 are in Phase 3. Port Huron, Michigan is the city with the most studies, however there are 26413 locations running at least one trial for this medication." - Anonymous Online Contributor